A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

Deficiency of functional C1-INH activity is an autosomal dominant genetic disorder that can be further classified into 2 types. Type I HAE, which accounts for approximately 85% of cases, occurs due to ...

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

Hereditary angioedema (HAE) doesn’t just cause swelling and discomfort; it also brings uncertainty to everyday life. This rare genetic condition causes sudden swelling attacks that are unpredictable, ...

Rapid swelling from hereditary angioedema can result from a variety of triggers. Doctors may use prophylactic medications to try and prevent these episodes, but managing stress and developing healthy ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) ...

Living with hereditary angioedema (HAE) means navigating a rare condition that causes painful swelling in various parts of the body, often including the face, hands, feet, genitals, abdomen, and ...

In the rare disease hereditary angioedema, or HAE, painful swelling attacks can happen anywhere in the body without warning. Drugs are available for acute treatment of these attacks, but they’re all ...

Cold compresses aren’t a first-line therapy for hereditary angioedema (HAE), but they may provide relief from swelling-related discomfort for some people. HAE is a rare genetic disorder that causes ...

HAE is characterized by recurrent episodes of severe swelling (angioedema). In June, the FDA approved CSL Limited’s (OTC: CSLLY) Andembry (garadacimab-gxii), the only treatment targeting factor XIIa ...